9th October 2023
AACR OVARIAN CANCER CONFERENCE PRESENTATION
• Data from preclinical studies in ovarian cancer presented at premier international conference in
Boston, USA.
• Results indicate that Amplia’s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer
• Data from these studies support clinical study of narmafotinib in ovarian cancer – with plans now commencing with leading international cancer specialists
I’m guessing it is something to do with this conference ...
.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.010(5.71%) |
Mkt cap ! $89.99M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.0¢ | 17.0¢ | $1.746M | 9.554M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 196996 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 287768 | 7 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| ATX (ASX) Chart |